President Trump, like former President Barack Obama, campaigned on the promise of taking on high drug prices. Trump, unlike Obama, is actually trying to keep that promise.
The White House and the Department of Health and Human Services in recent days rolled out dozens of policies, which, if enacted, will lower the market prices we pay for drugs, and could also lead to more innovation in the long run.
The predictable criticism of Trump’s plan, from Democrats and their friends in the drug industry and news media, either misunderstands or misrepresents the policies under debate.
Everyone agrees that drug prices in the U.S. are too high. One reason is the noncompetitive nature of the complex channels traveled by pharmaceuticals and their financing from research laboratory to patient.
Get the Exclusive
04.30.2024